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1286Objective: Cell therapy has received much attention for its potential to regenerate ischemic organs, but initial
clinical trials in aged patients did not replicate the dramatic benefits recorded in preclinical studies with young
animals. This study was designed to improve our understanding of age-related changes in the response to ische-
mic injury and the regenerative capacity of implanted cells in the context of cell therapy for older recipients.
Methods and Results: Restoration of regional perfusion after hind limb femoral artery ligation was impaired
(P< .05) in old (vs young) rats, reflecting approximately 50% reductions in circulating endothelial progenitor
cells and the release of vascular endothelial growth factor/basic fibroblast growth factor. Bone marrow stromal
cells from young or old donors implanted into the ischemic hind limbs of young or old rats restored regional per-
fusion. Specifically, we documented significantly greater (P< .05) angiogenic potential in young (vs old) donor
cells when recipient age was controlled and greater (P< .05) regenerative responses in young (vs old) recipients
when donor cell age was controlled. Contributing to these differences were significantly greater survival in young
(vs old) donor cells (in vitro and after implantation) and about 2-fold more production of vascular endothelial
growth factor/basic fibroblast growth factor and mobilization of endogenous endothelial progenitor cells in young
(vs old) rats in response to ischemia.
Conclusions: The outcome of cell therapy in older recipients is determined by a combination of age effects on the
donor cells and on the recipients’ endogenous responses. Donor cell age and recipient age are equally important
contributors to the outcome of cell therapy; thus, novel biointerventions will need to target both components of the
process. (J Thorac Cardiovasc Surg 2010;139:1286-94)Supplemental material is available online.
Autologous bonemarrow or blood cells can promote neovas-
cularization, which facilitates regeneration and helps to re-
store function within ischemic tissues.1-4 Principal among
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Encouraging results from the preclinical studies rapidly
sparked clinical trials in which autologous cells were im-
planted into infarcted myocardium to boost functional
regeneration.5 Unfortunately, the early results in patients
were less promising than predicted: for example, ameta-anal-
ysis of 10 recent clinical trials found cardiac ejection fraction
improved by only 3% when cells were infused after a myo-
cardial infarction.6 Notably, most preclinical studies were
performed in healthy, young animals, whereas the clinical
trials enrolled patients of advanced age with multiple comor-
bidities. Previous studies have extensively documented
diminished function in aged cells7-12; other reports suggest
that the aged cell recipient has a limited healing response (in-
cluding an attenuated bone marrow response to ischemia).13
The implication is that improving the outcome of cell therapy
in older patients will require addressing both donor cell func-
tioning and recipient responsiveness. However, before the
next generation of biointerventions can be designed, a better
understanding is required of the multiple effects of aging—
a main confounder in studies of autologous cell transplanta-
tion. Here, as a first step toward predicting which approach
will best enhance future clinical cell therapy trials, we inves-
tigate the combined effects of aging on donor cells and recip-
ients of cell therapy in a rat model of hind limb ischemia.gery c May 2010
Abbreviations and Acronyms
ANOVA ¼ analysis of variance
bFGF ¼ basic fibroblast growth factor
BMSC ¼ bone marrow stromal cell
BrdU ¼ bromodeoxyuridine
ELISA ¼ enzyme-linked immunosorbent assay
EPC ¼ endothelial progenitor cell
FITC ¼ fluorescein isothiocyanate
LDPI ¼ laser Doppler perfusion image
TUNEL ¼ terminal dUTP nick-end labeling
VEGF ¼ vascular endothelial growth factor
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Animals
We used female Lewis rats (young ¼ 6–8 weeks; old ¼ 60–64 weeks;
Harlan Sprague Dawley, Inc, Indianapolis, Ind). Animal procedures were
approved by the Animal Care Committee of the University Health Network,
and all animals received humane care in compliance with the ‘‘Guide for the
Care and Use of Laboratory Animals’’ (NIH No. 85-23, revised 1996).
Isolation, Expansion, and Characterization of Bone
Marrow Cells
Bone marrow stromal cells (BMSCs) were obtained from young or old
rats as described previously.4 Isolated cells were cultured, expanded (3 pas-
sages), and characterized by flow cytometry,2 as detailed in the online
E-Materials and Methods section.
Hind Limb Ischemia and Cell Transplantation
Ischemia was established in the right hind limbs of young and old rats, as
described previously1 and in the online E-Materials and Methods section.
Left hind limbs served as nonischemic controls.
Young and old rats were randomized into the following 6 groups (n¼ 8–
10 rats per group): young or old recipients of culture medium only (Y con-
trol, O control), young or old recipients of cells isolated from young donors
(Y-Y, Y-O), and young or old recipients of cells isolated from old donors
(O-Y, O-O). One day after hind limb ischemia was established, cells (5 3
106 BMSCs total in 0.3 mL phosphate-buffered saline solution) or culture
medium (control groups) were delivered by 5 separate injections into the
ischemic right thigh muscle.
Hind Limb Blood Perfusion
Perfusion in the hind limbs was measured with a laser Doppler perfusion
image (LDPI) analyzer (PeriScan PIM 3 Systems; Perimed AB, Ja¨rfa¨lla
Sweden), as described in the online E-Materials and Methods section, at 5
time points: before ischemia (day 0); immediately before cell transplantation
(day 1 after ischemia); and days 7, 14, and 21 after transplantation. The
LDPI index was calculated as the ratio of perfusion in the ischemic versus
the nonischemic hind limb.1
Calf Muscle Weight Loss
At 21 days after transplantation, calf muscles were harvested (n ¼ 8 per
group) and weighed. Loss of mass in the ischemic muscle was expressed as
the percent decrease in mass relative to the nonischemic (left) calf muscle.
Capillary and Arteriolar Densities in Ischemic Tissue
At 21 days after transplantation, capillary densities (ratio of capillaries/
muscle fibers) and arteriolar densities (average number of arteriole ringsThe Journal of Thoracic and Carper high-power field) were quantified in stained or immunostained cryosec-
tions from the ischemic hind limb muscles (n¼ 4 per group), as described in
the online E-Materials and Methods section.
In Vitro Donor Cell Apoptosis
BMSCs (3 3 105) isolated from young (n ¼ 6) or old (n ¼ 6) donor
rats were cultured in a hypoxic environment for 24 hours, as detailed in
the online E-Materials and Methods section. Apoptotic cells were de-
tected by a terminal dUTP nick-end labeling assay (TUNEL; Roche Di-
agnostics, Indianapolis, Ind) according to the manufacturer’s instructions,
and counted in 3 randomly selected fields per well by 2 blinded investi-
gators. TUNEL-positive cell counts were expressed as a percentage of
total cells.
In Vivo Implanted Cell Survival
Donor BMSCs labeled with bromodeoxyuridine (BrdU, Sigma Chemi-
cal Co, St Louis, Mo) before implantation were identified immunohisto-
chemically in the ischemic tissue at 21 days after transplantation and
quantified in 5 randomly selected fields per formalin-fixed tissue section
(n¼ 10 per group) as described in the online E-Materials and Methods sec-
tion. Implanted cell survival was expressed as the average number of BrdU-
positive nuclei per 0.2 mm2.
In Vitro and In Vivo Vascular Endothelial Growth
Factor (VEGF) and Basic Fibroblast Growth Factor
(bFGF) Protein Expression
BMSCs (33 105) from young or old donors (n¼ 6 per group) were cul-
tured in 24-well plates with serum-free medium, or incubated in a hypoxic
environment with serum-free medium for 24 hours. Conditioned medium
was collected, and VEGF and bFGF expression levels (expressed as pico-
grams per milligram total protein) were measured with enzyme-linked
immunosorbent assay (ELISA) kits (Quantikine; R&DSystems, Inc,Minne-
apolis, Minn).
Muscle samples (n ¼ 6 per group) were harvested from the ischemic
hind limbs of young and old rats at 7 days after cell transplantation, as de-
scribed in the online E-Materials and Methods section. VEGF and bFGF
levels were measured with the ELISA kits.
Endothelial Progenitor Cell (EPC) Mobilization
EPC-like mononuclear cells were quantified in peripheral blood and
spleen at 7 days after cell transplantation in young and old rats (and before
ischemia in Y control and O control; n ¼ 5 per group) as described in the
online E-Materials and Methods section. EPCs were identified by flow cy-
tometry as CD34þ/KDRþ cells.14,15
Statistical Analyses
Data are expressed as mean  SD. Analyses were performed with
GraphPad Prism 4 software (San Diego, Calif). Comparisons between
2 age groups with respect to muscle loss and capillary and arteriolar den-
sities in young and old rats, BrdUþ and TUNELþ cells counts, and in
vitro growth factor levels were carried out with unpaired, 2-tailed, un-
equal variance Student t tests. Two-way analyses of variance (ANOVA)
tested the main and interactive effects of age and time after ischemia on
LDPI or EPC recruitment. When F values were significant, Bonferroni
post-hoc tests were applied to specify significant differences among the
groups. One-way ANOVAs compared all groups studied with respect
to LDPI, capillary and arteriolar densities, or muscle loss at 21 days after
cell implantation, or growth factor levels and EPC recruitment at 7 days
after implantation. When F values were significant, Neuman–Keuls post-
hoc tests were applied to specify significant differences among the
groups. Correlation analyses were performed on the basis of group
mean values.diovascular Surgery c Volume 139, Number 5 1287
FIGURE 1. Angiogenic recovery after hind limb ischemia in young and old rats. A, Representative laser Doppler perfusion images (LDPI) taken in young
and old rats (Young, Old) over 22 days after surgically induced right hind limb ischemia (no cell or media treatment). B, Recovery of blood flow in the ischemic
limbs of young and old rats (ratio of perfusion in the ischemic to normal limb, or LDPI index; n¼ 10 per group). F¼ 3.43,P<.05.P values indicate significant
differences between age groups at time points indicated. C, Calf muscle weight loss (expressed as percent decrease in mass relative to the nonischemic calf
muscle) in young and old rats at 22 days after ischemic injury (n¼ 8 per group). D, Representative micrographs (magnification¼ 2003) illustrating capillaries
(purple¼ alkaline phosphatase staining) in the ischemic hind limb muscle of young and old rats 22 days after injury; graph quantifying capillary density (ratio
of capillaries to muscle fibers; n ¼ 4 per group). E, Representative micrographs (magnification ¼ 2003) illustrating arterioles (green ¼ a-smooth muscle
actin staining) in the ischemic tissue of young and old rats at 22 days after injury; graph quantifying arteriolar density (per 0.2mm2; n ¼ 4 per group). F
and G, Number of endothelial progenitor cells (EPCs; per 10,000 mononuclear cells [MNCs]) in peripheral blood (F ¼ 48.48, P< .001; F) and spleen (F
¼ 26.06, P< .001; G) of young and old rats on days 0 and 8 after ischemic injury (n ¼ 5 per group).
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Aging Impairs Angiogenesis in Response to Ischemia
To quantify the effect of age on tissue revascularization af-
ter an ischemic insult, we generated hind limb ischemia in
young and old rats. In both age groups, ischemic hind limb1288 The Journal of Thoracic and Cardiovascular Surperfusion (LDPI) decreased by 90% at 1 day after arterial
ligation. Recovery of regional perfusion over the following
21 days was significantly more rapid in young compared
with old rats (Figure 1,A andB), and calf weight loss was sig-
nificantly attenuated (Figure 1, C). Within the ischemicgery c May 2010
FIGURE 2. Angiogenic recovery after cell therapy.A,Representative laserDoppler perfusion images (LDPI) taken over 22 days after surgically induced right
hind limb ischemia; graph quantifying LDPI index at 21 days after cell implantation (n¼ 8–10 per group). B andC, Capillary density (capillaries/muscle fibers;
B) and arteriolar density (per 0.2mm2; C) in the ischemic hind limb at 21 days after cell implantation (n¼ 4 per group). D, Representative images illustrating
calf muscles from the right (R; ischemic) and left (L; nonischemic) hind limbs of a single rat at 21 days after cell implantation; graph quantifying calf muscle
weight loss (expressed as percent decrease inmass relative to the nonischemic calfmuscle; n¼ 8 per group). Allmeasurementswere performed in the following
groups: young or old recipients of culturemediumonly (Y, O), young or old recipients of bonemarrow stromal cells (BMSCs) isolated fromyoung donors (Y-Y,
Y-O), and young or old recipients of BMSCs isolated from old donors (O-Y, O-O). Brackets at base identify the groups involved in the 2 major comparisons:
recipient age was controlled to study the effect of donor cell age (solid bracket); donor cell age was controlled to study the effect of cell recipient age (broken
bracket). In parts A to D, ANOVA (F ¼ 28.47, ¼ 421.3, ¼ 217.5, ¼ 94.81, respectively; all P< .001) followed by Neuman–Keuls post-hoc tests indicated
significant differences (P<.05) for all group comparisons,with the following exceptions:O-O did not differ fromY, andY-Odid not differ fromO-Y (P>.05).
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and arteriolar density (assessed with a-smooth muscle actin
immunostaining) was 2.3-fold greater (Figure 1, E) in young
compared with old animals (all measures P< .05). To iden-
tify factors responsible for these age-related differences in
the angiogenic response to ischemia, we quantified EPCs
and levels of angiogenic factors in both groups. Before ische-
mia, young and old rats exhibited similar numbers of EPCs in
the circulation and the spleen (Figure 1, F andG). Eight days
after ischemia, EPC numbers increased significantly (P<
.05) in both age groups, but the response produced twice as
many EPCs in the young rats (P< .05; Figure 1, F and G).
Similarly, VEGF and bFGF levels were 1.9- and 2.1-fold
higher, respectively, in the ischemic tissue of young com-
pared with old rats (see Figure 3, A and B).
The Angiogenic Potential of Cell Therapy Is
Diminished by Older Donor Cells
To isolate the role of donor cell age from that of recipient
age in the outcome of cell therapy in a clinically relevant
model, we compared the angiogenic responses in old recip-
ients of BMSCs isolated from young or old donors.The Journal of Thoracic and CarDonor cell age did not affect BMSC phenotype: by flow
cytometry, more than 95% of all cells expressed CD29
and CD90.1, whereas less than 2% expressed CD34 and
CD45 (data not shown). However, old (compared with
young) donor cells were associated with significantly lower
regional perfusion (Figure 2, A) and capillary (Figure 2, B)
and arteriolar (Figure 2, C) densities in the old recipients
at 21 days after implantation, as well as significantly greater
calf weight loss (Figure 2, D) (reductions of up to 25%; all
measures P<.01), although old donor cells did produce sig-
nificant (P< .01) improvements on each of these variables
compared with medium (O control).
Angiogenic factor production and endogenous stem cell
homing were also reduced with the implantation of old (vs
young) cells. At 7 days after transplantation, increases (rel-
ative to O control) in both VEGF and bFGF levels within
the ischemic tissue of old recipients were doubled when
the donor cells were derived from young rather than old do-
nors (Figure 3, A and B). Increases in endogenous EPC
counts in the blood and spleen were approximately 1.6-
fold higher after implantation with young (vs old) cells (Fig-
ure 3, C and D) (all measures P< .01).diovascular Surgery c Volume 139, Number 5 1289
FIGURE 3. Factors affecting angiogenic recovery after cell therapy. A and B, Levels of vascular endothelial growth factor (VEGF; A) and basic fibroblast
growth factor (bFGF;B) in the ischemic hind limb muscle at 7 days after cell implantation (n¼ 6 per group). C and D, Number of endothelial progenitor cells
(EPCs; per 10,000 mononuclear cells [MNCs]) in peripheral blood (C) and spleen (D) at 7 days after cell implantation (n ¼ 5 per group). All measurements
were performed in the following groups: young or old recipients of culturemedium only (Y, O), young or old recipients of bonemarrow stromal cells (BMSCs)
isolated from young donors (Y-Y, Y-O), and young or old recipients of BMSCs isolated from old donors (O-Y, O-O). Brackets in part C identify the groups
involved in the 2 major comparisons: recipient age was controlled to study the effect of donor cell age (solid bracket); donor cell age was controlled to study
the effect of cell recipient age (broken bracket). In parts A to D), ANOVA (F ¼ 148.4, ¼ 233.7, ¼ 60.29, ¼ 59.34, respectively; all P< .001) followed by
Neuman–Keuls post-hoc tests indicated significant differences (P<.01) for all group comparisons, with the following exceptions: O-O did not differ from Y,
and Y-O did not differ from O-Y (P> .05).
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with old (vs young) donor cells. Twenty-one days after
cell transplantation, 50%more young than old BrdU pre-la-
beled BMSCs were identified within the ischemic tissue of
old recipients (P< .01; Figure 4, A), whereas no BrdU-pos-
itive cells were identified in the O control tissue. To investi-
gate the mechanisms underlying these differences, we tested
the stress responses of young and old donor cells in vitro. Af-
ter a 24-hour incubation in a hypoxic environment with se-
rum-free medium, BMSCs from old donors were 2.1 times
more susceptible to apoptosis (TUNEL) than those from
young donors (P< .01; Figure 4, B). Hypoxic cells from
both age groups released more angiogenic cytokines than
age-matched, nonhypoxic control cells; however, young
hypoxic cells secreted an average of 70% more VEGF and
bFGF than old hypoxic cells (P< .05; Figure 4, C and D).
The Angiogenic Response to Cell Therapy Is
Diminished in Older Recipients
To isolate the role of recipient age from that of donor cell
age in the outcome of cell therapy, we compared the angio-1290 The Journal of Thoracic and Cardiovascular Surgenic responses in young and old recipients of BMSCs
isolated from young donors.
At 21 days after cell implantation, both young and old cell
recipients exhibited significant and similar increases in re-
gional perfusion, blood vessel (capillary and arteriolar) densi-
ties, and calf muscle preservation relative to age-matched
(medium injected) controls (average increases of 45%, 41%,
186%, and 87%, respectively; P< .01; Figure 2), indicating
that the magnitude of the angiogenic response to cell therapy
was similar in young and old recipients. But importantly,
as discussed previously, all 4 measures were significantly
(P< .05) depressed in the old recipients of medium (O con-
trols) compared with Y controls. Consequently, the absolute
LDPI (Figure 2, A) and capillary and arteriolar densities
(Figure 2, B and C) were significantly greater in young com-
pared with old recipients of BMSCs (15%, 22%, and 43%
higher, respectively), and the absolute percentage weight loss
was reduced by38% in the ischemic limbs of young compared
with old cell recipients (Figure 2, D) (all measures P< .01).
We observed the same pattern of higher VEGF and bFGF
levels (44% and 19% higher, respectively; Figure 3, A andgery c May 2010
FIGURE 4. Factors contributing to the increased angiogenic potential of cells isolated from young donors. A, Representative micrographs (magnification¼
2003) illustrating bromodeoxyuridine (BrdU) labeling (purple) in the ischemic hind limb muscle of old recipients of young (Y-O) or old (O-O) bone marrow
stromal cells (BMSCs) prelabeled with BrdU, at 21 days after implantation; graph quantifying cell survival (BrdUþcells/0.2mm2; n¼ 10 per group). B, Rep-
resentative micrographs (magnification ¼ 2003) illustrating terminal dUTP nick-end labeling (TUNEL) staining (green ¼ apoptotic cells; blue ¼ nuclei
stained with 4,6-diamino-2-phenylindole) in BMSCs isolated from young or old rats (young cells; old cells) and cultured for 24 hours in hypoxic conditions
(with serum-free medium); graph quantifying apoptosis (percent TUNELþcells; n ¼ 6 per group). C and D, Levels of angiogenic cytokines (vascular endo-
thelial growth factor [VEGF], C; basic fibroblast growth factor [bFGF], D) secreted by young cells and old cells after 24 hours culture in hypoxic conditions
(with serum-free medium), and by age-matched controls (n ¼ 6 per group).
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(39% and 31% higher, respectively; Figure 3, C and D) at
7 days after cell implantation in young compared with old
recipients of BMSCs, despite similar significant increases
in these measures relative to the respective age-matched
medium recipients (all measures P< .01).
The blunted angiogenic response in old cell recipients was
associated with decreased survival of the implanted young
cells, inasmuch as significantly more BrdU-labeled BMSCs
were identified in the ischemic tissue of young compared
with old cell recipients (Y-Y: 31.45  2.22; Y-O: 24.1 
1.73 BrdU-positive cells per 0.2 mm2; P< .01).
The Combined Effects of Aging on Cell Recipients
and Donor Cells Determine the Efficacy of
Angiogenic Cell Therapy
To evaluate the combined effects of aging on donor cells
and recipients, we assessed (based on all groups studied) the
statistical relationship between perfusion in the ischemic
hind limb (LDPI at 21 days after cell transplantation) and
the local production of angiogenic cytokines or EPC num-
bers in the recipient blood or spleen at 7 days after transplan-
tation (Figure 5). All correlations were highly significantThe Journal of Thoracic and Car(r2>0.95 for all correlations; P< .001) and demonstrated
linear relationships between LDPI and each of the variables.
As illustrated by the linear relationships in Figure 5, all
cell recipients exhibited restoration of angiogenesis and per-
fusion in the ischemic hind limb; however, the relative de-
gree of functional recovery varied among groups owing to
the influence of age on the donor cells and the endogenous
responses from the recipients. Not surprisingly, the greatest
angiogenic response was in young recipients implanted with
young donor cells. But interestingly, we found that the an-
giogenic response in old recipients implanted with young
donor cells was similar to that in young recipients implanted
with old donor cells. This suggests that donor cell age and
recipient age may be equally important contributors to the
outcome of cell therapy. A 2-way ANOVA confirmed
significant (P< .01) main effects of both donor cell age
and recipient age. Finally, although improvements relative
to age-matched medium controls were observed in old re-
cipients implanted with old donor cells, LDPI in this group
was significantly lower than that in the other groups that re-
ceived cells and was similar to that in Y controls—an obser-
vation that also highlights the capacity for tissue repair in
untreated young animals. The correlations in Figure 5diovascular Surgery c Volume 139, Number 5 1291
FIGURE 5. Correlating perfusion with the underlying factors: Group relationships (A-D). Significant linear correlations are illustrated between mean laser
Doppler perfusion image (LDPI) index (at 21 days after cell implantation) and the followingmeasures (all at 7 days after implantation): mean levels of vascular
endothelial growth factor (VEGF; A) or basic fibroblast growth factor (bFGF; B) in the ischemic tissue; mean number of endothelial progenitor cells (EPCs;
per 10,000 mononuclear cells [MNCs]) in recipient blood (C) or spleen (D). All measurements were performed in the following groups: young or old recip-
ients of culture medium only (Y, O), young or old recipients of bone marrow stromal cells (BMSCs) isolated from young donors (Y-Y, Y-O), and young or old
recipients of BMSCs isolated from old donors (O-Y, O-O). All correlations were highly significant (P< .001).
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genic cytokines and the associated induction of endogenous
stem cell homing and neovascularization might account for
the range of functional outcomes among the different groups
of cell recipients.
DISCUSSION
This study provides the first demonstration of the effects
of aging (both separate and combined) on the response to
ischemic injury and the activity of implanted cells in the
context of cell therapy. We found that (1) old animals
had a reduced capacity to respond to hind limb ischemia
(and therefore, to subsequent cell therapy) by establishing
a blood vessel network to restore perfusion, and (2) the
implantation of aged (vs young) donor BMSCs induced
less angiogenesis and more loss of muscle mass in ischemic
recipients.
The mechanisms responsible for the age-related decline in
the efficacy of cell therapy remain unclear, but studies of the
aging process suggest numerous possibilities.9,16,17 Previ-
ous reports have established the limited ability of aged cells
to secrete angiogenic factors and documented the limited
capacity of older recipients to mobilize angiogenic progen-
itor cells, increase blood vessel density, or mitigate tissue
loss after arterial ligation.10,18 However, the relative contri-
butions of the limitations on these two components—cells
and recipients—have never been compared.1292 The Journal of Thoracic and Cardiovascular SurSeveral factors may account for the diminished effec-
tiveness of old donor cells. First, cells isolated from old
(vs young) donors have a reduced tolerance to ischemic
injury, which could explain their decreased survival within
ischemic muscle. The number of engrafted donor cells is
known to correlate with the magnitude of improvement
in perfusion, suggesting that reduced survival in old donor
cells could limit perfusion and vessel formation by
decreasing the overall biological stimulus exerted. In order
to address this issue, implanted cell survival could be
increased by transfecting the donor cells with survival
factors before transplantation.20 Second, we found that
BMSCs isolated from old donors produced less VEGF
and bFGF than those isolated from young donors in
response to ischemia, both in vitro and in vivo. Previous
studies indicated that an age-related reduction in VEGF
might limit the mobilization and survival or differentiation
of EPCs.10 We showed here that a limited release of an-
giogenic factors by old donor cells was associated with
fewer mobilized EPCs in the circulation and the spleen.
The limitations imposed on donor cells by increased age
could be addressed by rejuvenating donor cells from older
patients before implantation or by using allogeneic cells as
donors. We21,22 previously demonstrated that transfecting
BMSCs with genes to enhance angiogenesis improved
cell recruitment, and others have shown that healthy allo-
geneic BMSCs induced more angiogenesis in ischemicgery c May 2010
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ough new strategies will be required to induce prolonged
host tolerance of allogeneic cells.
A most important finding of this study is that the age-
diminished regenerative response of the recipient may be
an equally important contributor to the limited benefit of
cell therapy for older individuals. Young and old recipients
of BMSCs isolated from young donors exhibited similar
improvements in measures of angiogenesis relative to their
respective, age-matched controls, suggesting a similar
potential to respond to cell therapy. Therefore, the enhanced
outcomes of cell therapy in the young (vs old) recipients
were probably due to age-related differences in the regener-
ative response to the original ischemic injury, in which old
animals fared worse than young. These unique observations
have important therapeutic implications for older recipients
of cell therapy. To achieve the full benefit of implanted cells,
both the donor cells and the recipient will likely require new
therapeutic interventions. Rejuvenating the regenerative
capacity of older patients with multiple comorbidities
(such as diabetes or diffuse atherosclerosis) may be neces-
sary to boost angiogenesis.8 Bone marrow transplantation,
which has been used to restore marrow function in malig-
nant and benign diseases, could be used to renew marrow
regenerative capacity in these patients.24 Also, both rejuve-
nated autologous and allogeneic donor cells have been eval-
uated clinically for their potential to enhance bone marrow
function.
Our study is limited by the fact that we did not compare
different cell doses, but instead used a single dose that was
previously demonstrated effective in this model.1 As indi-
cated, increasing the number of engrafted cells improves
the response to cell therapy.19 In addition, we focused our
assessment on the angiogenic response to ischemia or cell
therapy and restricted our evaluation of the mechanisms
responsible to measurements of growth factor secretion
and EPC function. Although previous studies do suggest
that neovascularization potential is profoundly reduced
with aging,7,8 the outcome of cell therapy in this model is
certainly determined by a combination of factors in addition
to angiogenesis. However, now that we have established the
equal contributions of age on donor cells and recipient
responses, we anticipate that future investigations will pro-
vide more extensive assessments of the mechanisms in-
volved and identify new therapeutic targets. New
approaches might include, for example, inhibition of antian-
giogenic mediators or activation of alternate growth factors
in the angiogenic cascade.
The data presented here contribute to our understanding
of the discrepancy between results from preclinical studies
(performed in young animals), which demonstrated robust
angiogenic and functional responses to cell therapy, and
clinical trials (performed in older patients), which demon-
strated only limited restorative responses. We concludeThe Journal of Thoracic and Carthat the outcome of cell therapy in older recipients is deter-
mined by a combination of age effects on both donor cells
and recipients. To enhance the clinical effectiveness of cell
therapy for aged patients, future interventions should restore
the regenerative capacities of both the implanted cells and
the cell recipient.References
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E-MATERIALS AND METHODS
Isolation and Expansion of BMSCs
BMSCs were obtained by flushing the cavities of tibias and femurs from
young or old rats as described previously,E1 cultured in Iscove’s modified
Dulbecco’s medium (Gibco; Invitrogen Corporation, Carlsbad, Calif)
with 10% fetal bovine serum, 100 U/mL penicillin G, and 100 mg/mL strep-
tomycin, and placed into a humidified incubator at 37C with 5% carbon
dioxide. After 3 to 5 days, nonadherent hematopoietic cells were washed
away. Adherent BMSCs were expanded (3 passages) for transplantation.
Characterization of BMSCs
BMSCs were characterized by flow cytometry with various cell surface
markers.E2 In brief, the adherent cells were detached with a cell dissociation
solution according to the manufacturer’s instructions (Sigma), and 13 106
cells were stained for phycoerythrin-conjugated anti-CD90.1 (eBiosciences,
San Diego, Calif) and fluorescein isothiocyanate (FITC)–conjugated anti-
CD29, -CD45, -CD117, and -CD34 (BD Pharmingen, San Diego, Calif).
Rat IgG isotype control antibodies (BD Pharmingen) were used as controls.
All antibody incubations were carried out for 30 minutes at 4C in the dark.
Cells were analyzed by a Beckman Coulter EPICS XL flow cytometer with
EXPO32 ADC software (Beckman Coulter, Fullerton, Calif). The fluores-
cence intensity of 10,000 cells per sample was quantified.
Hind Limb Ischemia Model
The rat hind limb ischemia model was established previously.E3 In brief,
young (6–8 weeks old) and old (60–64 weeks old) rats were anesthetized in
an isoflurane chamber and then intubated and maintained with inhaled iso-
flurane (1%–2%) during the operation. To establish unilateral hind limb is-
chemia in each animal, the right common iliac artery, the promixal portion
of the right femoral artery, and the distal portion of the saphenous artery
were ligated with 5-0 silk and excised. Left hind limbs were left intact as
nonischemic controls.
Hind Limb Blood Perfusion
Blood perfusion in the hind limbs was measured with an LDPI analyzer
(PeriScan PIM 3 Systems) at 5 time points: before the operation at day 0 to
establish hind limb ischemia; immediately before cell transplantation at 1
day after ischemia; and 7, 14, and 21 days after transplantation. The perfu-
sion signal was subdivided into 6 different intervals, each displayed as a sep-
arate color, with low or no perfusion displayed as dark blue and highest
perfusion displayed as red. Before scanning was initiated, excess hind
limb hair was removed with a shaver, and each rat was placed on a 37C
heating plate for 15 to 20 minutes. After blood flow was scanned twice in
each region of interest (legs and feet), average flow values for ischemic
and nonischemic hind limbs were calculated by computer-assisted quantifi-
cation of the stored images. To minimize variations due to ambient light and
temperature, we calculated an LDPI index as the ratio of ischemic to non-
ischemic hind limb perfusion.E4
Capillary and Arteriolar Densities in Ischemic Tissue
At 21 days after transplantation, capillary densities and arteriolar densi-
ties were quantified in the ischemic hind limb muscles (n¼ 4 per group). So
that capillary densities could be assessed, the right adductor and semimem-
branous muscles were embedded in Tissue-Tek OCT compound (Sakura Fi-
netek, Torrance, Calif) and then snap-frozen in liquid nitrogen. Transverse
sections (5 mm thick) were stained with alkaline phosphatase and counter-
stained with eosin. Under light microscopy (Nikon, Tokyo, Japan), capillar-
ies were counted in 5 randomly selected, high-power fields per section by 2
different investigators blinded to the study conditions. So that overestimat-
ing or underestimating the number of capillaries due to myocyte atrophy or
interstitial edema could be avoided, capillary density was expressed as the
ratio of capillaries/muscle fibers.
Arteriolar densities were assessed by immunostaining serial cryosections
with an FITC-conjugated anti-a-smooth muscle actin antibody, and staining
the nuclei with 40,6-diamidino-2-phenylindole. The average number of
FITC-positive arteriole rings per high-power field was quantified with a Ni-
kon fluorescent microscope.
In Vitro Donor Cell Apoptosis
BMSCs (33 105) isolated from young (n ¼ 6) or old (n¼ 6) donor rats
were cultured in 24-well plates, in a hypoxic environment with serum-free
medium for 24 hours, and subsequently fixed in 2% paraformaldehyde for
10 minutes. Apoptotic cells were detected by a TUNEL assay, according to
the manufacturer’s instructions, and nuclei were stained with 40,6-diami-
dino-2-phenylindole (Sigma). TUNEL-positive cells were counted in 3 ran-
domly selected fields per well by 2 different investigators blinded to the
study conditions. Counts were expressed as the percent of apoptotic cells
(TUNEL-positive cells/total cells).
In Vivo Implanted Cell Survival
Donor BMSCswere labeled with 10 mmol/L BrdU for 24 hours, and then
implanted into ischemic muscle tissue. Thigh muscles were harvested (n ¼
10 per group) at 21 days after transplantation and fixed with 10% formalde-
hyde formalin. The fixed tissues were cut into 2-mm thick slices, embedded
in paraffin, and sectioned for histologic studies. So that the implanted
BMSCs could be identified, sections were immunostained with a monoclo-
nal antibody against BrdU (Caltag Laboratories, Camarillo, Calif). Im-
planted cell survival in the ischemic tissue was quantified in 5 randomly
selected fields from each section and expressed as the average number of
BrdU-positive nuclei per 0.2 mm2.
In Vitro and In Vivo VEGF and bFGF Protein
Expression
So that the secretion of angiogenic factors in BMSCs isolated from
young and old rats could be compared, 3 3 105 BMSCs from young and
old donors (n ¼ 6 per group) were cultured in 24-well plates with serum-
free medium for 24 hours or incubated in a hypoxic environment with
serum-free medium for 24 hours. The conditioned medium was collected,
and VEGF and bFGF expression levels were measured with ELISA kits
(Quantikine; R&D Systems).
So that VEGF and bFGF protein expression in the ischemic hind limbs
could be determined, muscle samples (n ¼ 6 per group) were harvested at 7
days after cell transplantation and homogenized in liquid nitrogen. Total
protein was extracted from 100 mg of powdered tissue in lysis buffer (20
mmol/L Tris [pH 7.4], 150 mmol/L NaCl, 1 mmol/L ethylenediaminetetra-
acetic acid, 1 mmol/L ethyleneglycol-bis-(b-aminoethylether)-N,N,N0N0-
tetraacetic acid, 1% Triton, 2.5 mmol/L Na pyrophosphate, 1 mmol/L b-
glycerolphosphate, 1 mmol/L vanadate (Na3VO4), 1 mg/mL leupeptin, 1
mg/mL pepstatin, and 1 mmol/L phenylmethylsulfonyl fluoride) for 1
hour on ice. After centrifugation at 10,000g for 10 minutes, the supernatant
was collected, and protein concentration was determined with a Bio-Rad
DC protein assay kit according to the manufacturer’s instructions. VEGF
and bFGF expression were measured with ELISA kits and normalized by
picograms per milligram of total protein.
EPC Mobilization
So that EPCmobilization from the bonemarrowcould be assessed after the
induction of hind limb ischemia, EPC-like mononuclear cells were quantified
in both peripheral blood and spleen. At 7 days after transplantation in young
and old rats (and before ischemia inY control andO control; n¼ 5 per group),
EPC-like mononuclear cells were isolated from blood (1 mL) and spleen by
centrifugation through a Histopaque-1083 density gradient (Sigma) and
then incubated on ice for 40 minutes with an FITC-conjugated anti-human
CD34antibody (Caltag) and aphycoerythrin-conjugatedanti-humanKDRan-
tibody (R&DSystems). The cellswerewashed twicewith phosphate-buffered
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saline containing 2% fetal bovine serum and 0.1% sodium azide, and EPCs
were identified by flow cytometry as CD34þ/KDRþcells.E5,E6
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